Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study.

European journal of clinical investigation - 1 Nov 2010

Nagueh Sherif F, Lombardi Raffaella, Tan Yanli, Wang Jianwen, Willerson James T, Marian Ali J

Abstract excerpt

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a genetic paradigm of cardiac hypertrophy. Cardiac hypertrophy is a major determinant of risk of sudden death and morbidity in HCM. Treatment with statins reverses hypertrophy in animal models of HCM. Thus, statins may afford therapeutic benefits in HCM. METHODS: We performed a feasibility study with atorvastatin to gather the pre-requisite data for designing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Atorvastatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiomegaly

Share to Cardiomyopathy, Hypertrophic

Share to Death, Sudden, Cardiac

Share to Heptanoic Acids

Share to Pyrroles

Share to Statistics as Topic

Source

Identifiers

PMID: 20629707
DOI: 10.1111/j.1365-2362.2010.02349.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study.PMID 20629707Read ↗

Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy.Semantic proximity Read ↗

Genetic basis for hypertrophic cardiomyopathy: implications for diagnosis and treatment.Semantic proximity Read ↗

Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline.Semantic proximity Read ↗

[Molecular targets and novel pharmacological options to prevent myocardial hypertrophic remodeling].Semantic proximity Read ↗

Experimental therapies in hypertrophic cardiomyopathy.Semantic proximity Read ↗

Cardiac Hypertrophy: Mechanisms and Therapeutic OpportunitiesSemantic proximity Read ↗

Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study.Semantic proximity Read ↗

The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study.Semantic proximity Read ↗

Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression.Semantic proximity Read ↗

Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy.Semantic proximity Read ↗

Signaling mechanisms in thyroid hormone-induced cardiac hypertrophy.Semantic proximity Read ↗

Left ventricular hypertrophy subtype and long-term mortality in those with subclinical cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis (MESA)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.